Prior to coming on to co-found Spinal Elements, Blain served in various roles with medtech companies Smith & Nephew (NYSE:SNN), Alphatec (NSDQ:ATEC) and NuVasive Inc. (NSDQ:NUVA). Blain is replacing Chris Fair, who will stay on as a board member with the company.
“I am excited by the opportunity to lead our talented team of employees and partners and create an even more vibrant and dynamic Spinal Elements in the years to come. I thank Chris Fair and the other members of our board of directors for their confidence. Going forward, Spinal Elements will continue to be focused on innovation and execution, driven by differentiated technologies and premium customer service, and we will move quickly to scale new ideas and opportunities into this dynamic marketplace,” Blain said in a press release.
“Jason has inspired many of Spinal Elements’ most exciting technologies – past, present and future – while also fostering a team-oriented culture in each position he has held during his career. I look forward to supporting Jason and the company across all future endeavors,” Fair said in a prepared statement.
The company also announced plans to move its global headquarters to its Carlsbad, Calif.-based location and reiterated that the move will have “minimal impact on Spinal Elements’ Marietta, Ga.-based operations and employees.”
“The company remains committed to its Marietta campus and our employees based there,” Blain said in a prepared release.
Prior to joining Sanofi, Couldwell held a number of roles at Smith & Nephew including European orthopedics prez and sales & marketing senior VP of the advanced wound management biz.
“Since being appointed to the board in 2013 I have been impressed with the great commercial potential of our dCELL platform. The recent acquisition of CellRight Technologies has increased the market potential and provided a highly complementary product range in the $1.7 billion. US bone graft and substitute market. I am delighted to be appointed CEO and look forward to leading the Group through the integration of CellRight and expansion of commercial activities as we execute our commercial strategy and grow our market share throughout the US and the rest of the world,” Couldwell said in a prepared statement.
“The board and I are delighted to welcome Steve as the Group’s new CEO. He has an exceptional track record of growing businesses and the Board firmly believes that Steve has the required skillset and experience to guide the Group along the pathway to profitability. Alongside this, Steve has an in-depth knowledge of the Group thanks to his years as a non-executive director making him an ideal candidate for this position,” board chair John Samuel said in a press release.
Cardiac device developer MedLumics said this week it tapped former venture capital firm Seroba Lifesciences partner James Greene as its new chief executive officer.
Prior to his time at Seroba, Greene helped found and lead cardiovascular device companies in the US and Europe including Verso Technologies, APK Advaned Medical Technologies, APICA Cardiovascular and MitralSolutions. Greene has also held positions at large firms including Medtronic (NYSE:MDT), Guidant and Abbott (NYSE:ABT).
“I am honored to be chosen to lead MedLumics as CEO. MedLumics’ innovative AblaView optically guided ablation technology enables clinicians to finally confirm in real time the creation of transmural scars without relying on a surrogate marker. The gravity of this innovation is the potential to reduce recurrence rates of AF, improve patient care, and provide a more cost-effective solution for the treatment of cardiac arrhythmias in today’s value-based medicine environment. MedLumics has a stellar team of professionals focused on developing innovative product solutions that offer clinicians better options for treating patients who suffer from AF and other arrhythmias,” Greene said in prepared remarks.
MedLumics said that in addition to the new CEO, it added Giovanni Leo to its board of directors.
“There is a growing need for new technologies to further advance the catheter ablation treatment of arrhythmias, and MedLumics has an opportunity to deliver on this with its highly advanced optics technology. I look forward to lending my expertise as the company focuses on raising the bar in this field,” Leo said in a press release.
The Medical Device Innovation Consortium said this month that its current prez & CEO William Murray will step down from his position on February 2 as he looks to return to the private sector.
The MDIC board said it has initiated a search for an individual to replace Murray as CEO.
“Over the past four years, it has been my honor and privilege to lead MDIC as we have grown from concept to an established part of the ecosystem in accelerating patient access to safe and effective life changing innovation. I am extremely proud of what we have accomplished. The organization is fortunate to be led by a board of senior leaders throughout the medtech ecosystem, supported by an incredible group of member volunteers and dedicated MDIC staff that give me great confidence we will achieve a smooth transition. My decision to return to the private sector has been difficult and emotional; we have built something very unique and rewarding at MDIC. Announcing my intention 3 months prior to leaving was the right decision to allow MDIC to move forward in a planned manner. I want to thank the MDIC board for their support as I worked through this process,” Murray said in a prepared release.
“The board of directors for MDIC would like to thank Bill for his leadership and contribution to advancing regulatory science for patients and expanding into real world data coordination. We wish him well going forward as he returns to the private sector to pursue other opportunities. MDIC is an integral part of the medtech ecosystem, the board is committed to find the next CEO leader that has the vision, passion and commitment to build on MDIC’s success.” MDIC board chair & Abiomed prez & CEO Mike Minogue said in a press release.
“MDIC has made great progress under Bill’s leadership these past four years. The organization has evolved into an integral partner with patients, industry and the FDA in addressing the most challenging regulatory science issues required for faster, safer and more efficient development, assessment and review of life-changing medical technologies. The FDA looks forward to continued collaborations with MDIC and its new leadership,” FDA Center for Devices and Radiological Health director Dr. Jeffrey Shuren said in a prepared statement.
Kenny has operated as COO at Cardiovascular Systems since February 2015, and served as exec VP of sales & marketing since May 9, 2011
The company said that it plans to enter into a separation agreement with Kenny in the future, and that it will disclose the terms of the separation agreement following execution by all parties.